Skip to main content

Market Overview

Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation

Share:
Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation

SUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI.

The Analyst

Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate.

The Thesis

The reduction in developmental myosin revealed by Summit Therapeutics with interim data from the PhaseOut DMD trial, as well as magnetic resonance spectroscopy data, strongly backs the efficacy of ezutromid, Zhong said in a Wednesday note.

DMD is the most common form of muscular dystrophy, which results from the lack of dystrophin, a protein responsible for maintaining healthy muscle function.

The PhaseOut trial is an open-label, multicenter trial with 40 patients in the U.S. and U.K. ages 5-10 years. 

"We do not believe investors fully appreciate the encouraging efficacy signal demonstrated by the 24-week data from the PhaseOut DMD study, and that the upcoming 48-week data in 3Q18 should be a strong catalyst for Summit shares," Zhong said. 

Janney expects FDA approval of ezutromid in 2021 following the completion of a placebo-controlled study.

Since all DMD patients are eligible for treatment, Zhong forecast significant commercial potential.

Ridinilazole for CDI adds more potential to Summit's pipeline, the analyst said. The company received a $62-million Biomedical Advanced Research and Development Authority award that "highlights both the significant unmet medical need and the program's strong prospect." 

The Price Action

Summit Therapeutics shares were down marginally at $13.74 at the close Friday.

Related Links:

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Cross-section of a Duchenne muscular dystrophy patient's muscle by the Centers for Disease Control and Prevention via Wikimedia. 

Latest Ratings for SMMT

DateFirmActionFromTo
Nov 2020HC Wainwright & Co.DowngradesBuyNeutral
Mar 2020HC Wainwright & Co.Initiates Coverage OnBuy
Jun 2018Janney Montgomery ScottDowngradesBuyNeutral

View More Analyst Ratings for SMMT
View the Latest Analyst Ratings

 

Related Articles (SMMT)

View Comments and Join the Discussion!

Posted-In: CDI DMDAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
GOTUCitigroupDowngrades12.0
ATERRoth CapitalMaintains25.0
FMTXSVB LeerinkMaintains54.0
TALCitigroupDowngrades
PLXSLoop CapitalMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com